{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:15:54Z","timestamp":1775841354985,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Previous RCTs and meta-analyses observed an increased occurrence of atrial fibrillation (AF) associated with ivabradine use. Nonetheless, these studies were not focused on AF diagnosis, and it remains unclear whether this observed increase is due to a direct effect of ivabradine or just an augmented AF detection. The latter mechanism could arise from a greater heart-rate differential between sinus rhythm and AF under ivabradine, potentially intensifying symptoms and prompting earlier clinical evaluation. If this hypothesis is true, an earlier diagnosis of AF, and subsequent earlier prophylaxis with anticoagulants, may result in a reduced incidence of ischemic cerebrovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a meta-analysis of the existing literature (calculating the ratio between ischemic cerebrovascular events and AF) combined with a disproportionality analysis of individual case safety reports of suspected adverse drug reactions. In the disproportionality analysis, we also included beta-blockers as a comparator group, given their dromotropic effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 555 studies screened in the meta-analysis, only three were considered eligible. The ratio between ischemic cerebrovascular events and AF with ivabradine was lower than with placebo (RR 0.74, 95% CI 0.62\u20130.89; p &amp;lt; 0.001). In the FAERS, AF was disproportionally reported with both ivabradine and beta-blockers (Information Component 0.84, 95% CI 0.43\u20131.14 and Information Component 0.53, 95% CI 0.44\u20130.60), while ischemic cerebrovascular events only with beta-blockers (Information Component 0.25, 95% CI 0.18\u20130.31).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings raise the hypothesis that ivabradine facilitates an increased diagnosis rather than playing a direct role in causing AF. Prospective studies with continuous ECG monitoring and standardized endpoints are needed to clarify the temporal and mechanistic relationship between ivabradine, AF recognition, and cerebrovascular risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1638923","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:37:05Z","timestamp":1763534225000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ivabradine, atrial fibrillation and stroke: a combined meta-analysis and FAERS disproportionality analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Alberto","family":"Spadotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Fusaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Carelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milo","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Ciubine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Diemberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/eurheartj\/ehaa164","article-title":"Cancer unmasked by bleeding during anticoagulant therapy: when a problem may become an opportunity","volume":"43","author":"Andreotti","year":"2022","journal-title":"Eur. Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/heartjnl-2018-314381","article-title":"Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis","volume":"105","author":"Beggs","year":"2019","journal-title":"Heart Br. Card. Soc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/ejhf.2870","article-title":"Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction","volume":"25","author":"B\u00f6hm","year":"2023","journal-title":"Eur. J. Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.amjmed.2014.11.026","article-title":"Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF pilot general registry","volume":"128","author":"Boriani","year":"2015","journal-title":"Am. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"iii355","DOI":"10.1093\/ehjci\/eux159.005","article-title":"1669Increased rate of previous stroke in asymptomatic\/minimally symptomatic versus symptomatic patients with newly detected atrial fibrillation in Western Europe - results from the GLORIA-AF registry","volume":"19","author":"Christow","year":"2017","journal-title":"Europace"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front. Drug Saf. Regul."},{"key":"B7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jaccao.2023.02.001","article-title":"Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients","volume":"5","author":"Diamond","year":"2023","journal-title":"JACC CardioOncology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.phrs.2006.03.006","article-title":"Funny channels in the control of cardiac rhythm and mode of action of selective blockers","volume":"53","author":"DiFrancesco","year":"2006","journal-title":"Pharmacol. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e000512","DOI":"10.1136\/bmjno-2023-000512","article-title":"Is there a temporal relationship between atrial fibrillation and stroke? A review","volume":"6","author":"Dlima","year":"2024","journal-title":"BMJ Neurol. Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/ejhf.3071","article-title":"Interaction of heart failure and stroke: a clinical consensus statement of the ESC council on stroke, the heart failure association (HFA) and the ESC working group on thrombosis","volume":"25","author":"Doehner","year":"2023","journal-title":"Eur. J. Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.hrthm.2023.02.012","article-title":"Ivabradine for controlling heart rate in permanent atrial fibrillation: a translational clinical trial","volume":"20","author":"Fontenla","year":"2023","journal-title":"Heart Rhythm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet Lond. Engl."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1093\/eurheartj\/ehv451","article-title":"Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study","volume":"36","author":"Fox","year":"2015","journal-title":"Eur. Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40264-023-01391-4","article-title":"Enhancing transparency in defining studied drugs: the open-source living DiAna dictionary for standardizing drug names in the FAERS","volume":"47","author":"Fusaroli","year":"","journal-title":"Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.31219\/osf.io\/h5w9u","article-title":"Causal inference tools for pharmacovigilance: using causal graphs to systematize biases, plan disproportionality analyses, and reduce the risk of spin","author":"Fusaroli","year":""},{"key":"B19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1161\/circ.104.17.2118","article-title":"ACC\/AHA\/ESC guidelines for the management of patients with atrial fibrillation: executive summary A report of the American college of cardiology\/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the north American society of pacing and electrophysiology","volume":"104","author":"Fuster","year":"2001","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"28","author":"Gatti","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40119-013-0024-1","article-title":"Ivabradine versus beta-blockers in patients with conduction abnormalities or left ventricular dysfunction undergoing cardiac surgery","volume":"3","author":"Iliuta","year":"2014","journal-title":"Cardiol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/europace\/euac144","article-title":"Searching for atrial fibrillation: looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paper","volume":"25","author":"Kalarus","year":"2023","journal-title":"EHRA position Pap. Eur."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1503\/cmaj.060110","article-title":"Re-examining the efficacy of -blockers for the treatment of hypertension: a meta-analysis","volume":"174","author":"Khan","year":"2006","journal-title":"Can. Med. Assoc. J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.cjca.2014.01.006","article-title":"Atenolol vs nonatenolol \u03b2-Blockers for the treatment of hypertension: a meta-analysis","volume":"30","author":"Kuyper","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"euad272","DOI":"10.1093\/europace\/euad272","article-title":"Asymptomatic atrial fibrillation among hospitalized patients: clinical correlates and in-hospital outcomes in improving care for cardiovascular disease in china-atrial fibrillation","volume":"25","author":"Lin","year":"2023","journal-title":"Europace"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet Lond. Engl."},{"key":"B29","doi-asserted-by":"publisher","first-page":"euad226","DOI":"10.1093\/europace\/euad226","article-title":"Atrial fibrillation and stroke prevention: 25 years of research at EP europace journal","volume":"25","author":"Lip","year":"2023","journal-title":"Eur. J. Eur."},{"key":"B30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/ehjcvp\/pvz006","article-title":"Ivabradine for heart failure: regulatory differences in Europe and United States","volume":"5","author":"Marciniak","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/europace\/euac062","article-title":"Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET\/EHRA consensus conference","volume":"25","author":"Schnabel","year":"2023","journal-title":"Europace"},{"key":"B34","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/clc.22578","article-title":"The risk of atrial fibrillation with ivabradine treatment: a meta-analysis with trial sequential analysis of more than 40000 patients","volume":"39","author":"Tanbo\u011fa","year":"2016","journal-title":"Clin. Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/ije\/dyaa213","article-title":"Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations","volume":"50","author":"Tennant","year":"2021","journal-title":"Int. J. Epidemiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur. Heart J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/FJC.0000000000001209","article-title":"Ivabradine and atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"79","author":"Wang","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1043714","DOI":"10.3389\/fphar.2022.1043714","article-title":"Beta-blockers in cardiac arrhythmias\u2013Clinical pharmacologist\u2019s point of view","volume":"13","author":"Wo\u0142owiec","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.thromres.2020.04.017","article-title":"Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: a network meta-analysis from 5 clinical trials","volume":"190","author":"Zhang","year":"2020","journal-title":"Thromb. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/ph16010098","article-title":"Cardiovascular toxicities of ibrutinib: a pharmacovigilance study based on the United States food and drug administration adverse event reporting system database","volume":"16","author":"Zheng","year":"2023","journal-title":"Pharmaceuticals"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1638923\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:37:06Z","timestamp":1763534226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1638923\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":43,"alternative-id":["10.3389\/fphar.2025.1638923"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1638923","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1638923"}}